Rationally designed synthetic vectors for therapeutic nucleic acid delivery against human cytomegalovirus infection
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Xuemei Ge und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers The State University of New Jersey, Newark, New J…. Hauptthemen laut MEDLINE: Immediate-Early Proteins, Nucleic Acids, Cytomegalovirus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Natural Science Foundation of China, National Institutes of Health.
Abstract (Originalsprache)
RNA therapy represents a great way to precisely regulate cellular processes by modulating the gene expression. Despite this potential, a profound gap exists in our knowledge of how to subsequently deliver these RNAs into the specific target cells and turn therapeutically active RNAs into practical medicines. An advanced series of interlocked, thermodynamically self‐regulated processes that enable the precise assembly of functional synthetic carriers of siRNA to the target cells in vivo was developed. To demonstrate the efficacy of this delivery system, we used it to treat human cytomegalovirus (HCMV) infection in a humanized mouse model. In this study, we use small interfering RNA (siRNA) and small complementary RNA (scRNA) to inhibit the expressions of two HCMV genes, IE1 and IE2. The auto‐regulated nanocarrier polywraplex with core‐shell structure was designed to condense and package these RNAs for delivering. To allow these particles recognize the HCMV‐infected cells, a ligand was coupled on the surface of nanoparticle, which would specifically target the HCMV‐encoded CX 3 CL 1 chemokine receptor presented in the HCMV‐infected cells. The results demonstrated that the polywraplex conjugated with the target molecule CX 3 CL 1 effectively and specifically delivered the siRNA/scRNA to HCMV infected cells and inhibited virus growth in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers The State University of New Jersey, Newark, New Jersey, USA.
- Department of Food Science and Technology, College of Light Industry Science and Engineering, Nanjing Forestry University, Nanjing, People's Republic of China.
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen Univers…
- Department of Microbiology, Howard University College of Medicine, Washington, District of Columbia, USA.
- Center for BioDelivery Sciences, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
ORCID-Profile: Dabbu K Jaijyan
Förderung
- NIDDK NIH HHS
- National Natural Science Foundation of China
- National Institutes of Health
Zitieren
APA
Ge, X., Jaijyan, D. K., Wang, W., Cheng, T., Tang, Q., Wu, F., Jin, T., & Zhu, H. (2023). Rationally designed synthetic vectors for therapeutic nucleic acid delivery against human cytomegalovirus infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.28586
Vancouver
Ge X, Jaijyan DK, Wang W, Cheng T, Tang Q, Wu F, et al. Rationally designed synthetic vectors for therapeutic nucleic acid delivery against human cytomegalovirus infection. Journal of Medical Virology. 2023. doi:10.1002/jmv.28586
BibTeX
@article{Ge2023,
author = {Ge, Xuemei and Jaijyan, Dabbu K and Wang, Wei and Cheng, Tong and Tang, Qiyi and Wu, Fei and Jin, Tuo and Zhu, Hua},
title = {Rationally designed synthetic vectors for therapeutic nucleic acid delivery against human cytomegalovirus infection},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28586}
}
EUVIMED